样本量推导是任何验证性试验规划阶段的关键要素。样本量通常基于对最大可接受I类错误率和最小期望功效的约束来推导。这里,功效依赖于未知的真实效应量。在实践中,功效通常要么针对最小相关效应量计算,要么针对一个可能的点备择假设计算。前者在最小相关效应接近零假设时可能存在问题,从而需要过大的样本量。后者则值得怀疑,因为它没有考虑关于可能备择效应量的先验不确定性。对频率学派试验的样本量推导采取贝叶斯视角,自然成为一种调和关于备择效应量相对先验合理性的论点与基于效应量相关性的观点的方法。文献中已经提出了许多关于如何在实践中实施这种“混合”方法的建议。然而,诸如保证(assurance)、成功概率(probability of success)或期望功效(expected power)等关键量在文献中常常以微妙不同的方式定义。从传统的、完全频率学派的样本量推导方法出发,我们为最常用的“混合”量推导出一致的定义,并强调它们之间的联系,然后讨论并展示它们在临床试验样本量推导背景下的应用。
英文摘要:
Sample size derivation is a crucial element of the planning phase of any confirmatory trial. A sample size is typically derived based on constraints on the maximal acceptable type I error rate and a minimal desired power. Here, power depends on the unknown true effect size. In practice, power is typically calculated either for the smallest relevant effect size or a likely point alternative. The former might be problematic if the minimal relevant effect is close to the null, thus requiring an excessively large sample size. The latter is dubious since it does not account for the a priori uncertainty about the likely alternative effect size. A Bayesian perspective on the sample size derivation for a frequentist trial naturally emerges as a way of reconciling arguments about the relative a priori plausibility of alternative effect sizes with ideas based on the relevance of effect sizes. Many suggestions as to how such `hybrid' approaches could be implemented in practice have been put forward in the literature. However, key quantities such as assurance, probability of success, or expected power are often defined in subtly different ways in the literature. Starting from the traditional and entirely frequentist approach to sample size derivation, we derive consistent definitions for the most commonly used `hybrid' quantities and highlight connections, before discussing and demonstrating their use in the context of sample size derivation for clinical trials.
From aggressive to conservative early stopping in Bayesian group sequential designs
The George Institute for Global Health, Imperial College London(乔治全球健康研究院,伦敦帝国理工学院);Imperial Clinical Trials Unit, Imperial College London(伦敦帝国理工学院临床试验中心);School of Mathematics, University of Bristol(布里斯托大学数学学院);The George Institute for Global Health, University of New South Wales(乔治全球健康研究院,新南威尔士大学)
adabay: an R package for rapid evaluation and calibration of Bayesian group sequential designs across common endpoint types
The George Institute for Global Health, Imperial College London(全球健康乔治研究所,伦敦帝国理工学院);Imperial Clinical Trials Unit, Imperial College London(伦敦帝国理工学院临床试验中心);School of Mathematics, University of Bristol(布里斯托大学数学学院)
Rapid evaluation and calibration of Bayesian group sequential designs via conjugate-mixture semi-simulation
The George Institute for Global Health, Imperial College London(乔治全球健康研究院,伦敦帝国理工学院);Imperial Clinical Trials Unit, Imperial College London(伦敦帝国理工学院临床试验中心);School of Mathematics, University of Bristol(布里斯托大学数学学院);The George Institute for Global Health, University of New South Wales(乔治全球健康研究院,新南威尔士大学)
A Workflow for Evaluating Regional Treatment Effect Heterogeneity in Multi-Regional Clinical Trials
China Novartis Institutes for BioMedical Research Co.(中国诺华生物医学研究有限公司);Department of Biostatistics, School of Public Health, Peking University(北京大学公共卫生学院生物统计系);Peking University Cancer Hospital(北京大学肿瘤医院);Advanced Methodology and Data Science, Novartis Pharma AG(诺华制药AG高级方法与数据科学部);Advanced Methodology and Data Science, Novartis Pharmaceuticals Corporation(诺华制药公司高级方法与数据科学部);Department of Public Health Sciences, University of Chicago(芝加哥大学公共卫生学系);Biostatistics CRM/NS/IMM, Advanced Quantitative Sciences, Global Drug Development Division, Novartis Pharma K.K.(日本诺华制药K.K.全球药物开发部高级定量科学生物统计CRM/NS/IMM);Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute(北京大学肿瘤医院及研究所癌变与转化教育部重点实验室)